- Sai Life Sciences, a global Contract Research, Development & Manufacturing Organization (CRO-CDMO), has expanded its drug metabolism and pharmacokinetics (DMPK) capabilities.
- The expansion includes the addition of 25,000 sq. ft. of state-of-the-art labs equipped with cutting-edge instrumentation enabling high-end automation.
- The company has also hired globally, resulting in nearly 3x growth of the team size.
Sai Life Sciences, a global Contract Research, Development & Manufacturing Organization (CRO-CDMO), has made a significant move in the pharmaceutical industry.The company has expanded its drug metabolism and pharmacokinetics (DMPK) capabilities. This expansion is aimed at offering global big pharma clients cutting-edge, end-to-end DMPK services.
The expansion comprises the addition of 25,000 sq. ft. of state-of-the-art labs equipped with the latest technology for high-end automation.The expansion is a strategic move to meet the increasing demand from innovator companies looking to diversify their supply chains.
As Krishna Kanumuri, CEO & Managing Director of Sai Life Sciences, said, “The focus of innovator companies on diversifying their supply chains bodes well for Indian CROs-CDMOs like ours. This expansion in our DMPK capabilities demonstrates our commitment and appetite for large, complex programs and our readiness to offer world-class DMPK services at scale.”
Sauri Gudlavalleti, Chief Operating Officer said, “The latest expansion of DMPK capabilities augments our integrated drug discovery (IDD) offerings. We have now emerged as a one-stop provider of DMPK services with high-level automation and the latest technologies. This coupled with our world-class MedChem, Biology, DMPK and Toxicology under one roof, we are better prepared than ever to offer end-to-end IDD services to global clients.”
The company’s DMPK team has experience of working with over 80 clients across the USA and UK, supporting diverse drug discovery programs for various drug modalities- small molecules, PROTACs, molecular glues, and peptides. The expansion of its Vivarium for supporting animal efficacy, PK-PD, and safety studies is underway and is expected to be ready by the end of this quarter. Sai Life Sciences also has plans to invest in niche areas such as peptides, oligos, and large molecules to strengthen its discovery capabilities.
Overview of outsourcing trends 
